Worldwide News

GlobalData has predicted that the arrival of biosimilar therapies in the EU will continue to fall in the coming years following a wave pattern that has been occurring since 2006.   GlobalData’s senior drugs database analyst Quentin Horgan notes that we are currently in the downward trajectory of a wave that peaked in 2018, and it is likely […]

Benchling, the biotechnology cloud R&D platform used by organisations including Regeneron, Gilead and Pfizer, hosted a virtual event on September 14 at 8 am PT / 11 am ET called Drive Innovation from Discovery to Development, where the company announced its entry into the Early Development market, launching new solutions that allow scientists to move from research through development within […]

Pharming Group has announced the topline results from two randomised, open label, controlled, pilot clinical trials of patients hospitalised with Covid-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the seven-point WHO ordinal scale on Day Seven.  In the US study, which had included […]

Hutchmed has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) for amdizalisib (HMPL-689), a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma (FL), a subtype of non-Hodgkin’s lymphoma (NHL).  Drug candidates with BTD may be considered for conditional approval and […]

Nottingham, UK-based contract research organisation (CRO) Cellomatics Biosciences has reported year-on-year organic revenue growth of 30% since its inception in 2015, as demand for its preclinical and early discovery phase laboratory services and expertise continues to increase.   Based at BioCity Nottingham, Cellomatics is a specialist preclinical CRO with expertise in five main therapeutic areas: oncology, immuno-oncology, immunology, inflammation and respiratory. Despite the challenges […]

Beckley Psytech has dosed the first patient in a world-first clinical trial exploring the effects of psilocybin for treating Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA).   The outcome of the Phase Ib study, with proof-of-concept efficacy data, is expected to be available in early 2022. The clinical trial is being conducted as part of Beckley Psytech’s ongoing collaboration […]

Vaccination is the most effective method of preventing infectious diseases, and is considered one of the greatest achievements in medicine. This brochure, released by Sartorius, is designed to demonstrate precision and safety at its finest.   Until today, various vaccines against several crucial diseases (including influenza, chicken pox, or HPV) have been developed that save millions of […]

Enterprise Lithuania and the Lithuanian Biotechnology Association has announced that in 2020, the Lithuanian biotechnology sector grew by a record 87% and accounted for 2.5% of the Baltic nation’s GDP. Industry leaders gathering at the upcoming Life Sciences Baltics forum are now calling for more international collaborations, increased investment and ongoing government support to continue […]

Valneva has received a termination notice from the UK Government (HMG) in relation to the Supply Agreement for its Covid-19 vaccine candidate, VLA2001. The contract provides HMG with the right to terminate. HMG has alleged that the company is in breach of its obligations under the Supply Agreement, which the company denies.  Valneva is continuing […]

Amgen UK’s first-in-class medicine sotorasib (a targeted KRAS G12C inhibitor formerly named AMG 510) has become the first new cancer therapy to receive Conditional Marketing Authorisation for use1 across England, Scotland and Wales by the Medicines and Healthcare products Regulatory Agency (MHRA) under Project Orbis. This authorisation follows a review of sotorasib’s role in treating patients with previously treated locally advanced or metastatic non-small […]